At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02595 GENFLEET-B
Not Yet Opened 09-08 16:08:36
27.060
-0.820
-2.94%
High27.860Low26.700Vol772.40K
Open27.500D1 Closing27.880Amplitude4.16%
Mkt Cap10.39BTradable Cap9.53BTotal Shares384.00M
T/O20.86MT/O Rate0.22%Tradable Shares352.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
GenFleet Therapeutics (GENFLEET-B) Buys Back 57,000 H-Shares, Treasury Position Doubles to 0.03% of Stock in Issue
Bulletin Express  ·  09-08 20:23
GenFleet Therapeutics (GENFLEET-B) Buys Back 57,000 H-Shares, Treasury Position Doubles to 0.03% of Stock in Issue
Genfleet-B Completes Share Buyback Worth HK$1.54 Million
Stock News  ·  09-08 20:11
Genfleet-B Completes Share Buyback Worth HK$1.54 Million
Genfleet Therapeutics Files HKEX Next-Day Disclosure, Reports Share Repurchase at HKD 27.05
Reuters  ·  09-08 20:08
Genfleet Therapeutics Files HKEX Next-Day Disclosure, Reports Share Repurchase at HKD 27.05
Hong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B
Stock News  ·  09-04
Hong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B
GenFleet Therapeutics Buys Back 20,000 H-Shares for HKD 0.55 Million, Lifting Treasury Stock to 59,000 Shares
Bulletin Express  ·  09-03
GenFleet Therapeutics Buys Back 20,000 H-Shares for HKD 0.55 Million, Lifting Treasury Stock to 59,000 Shares
GENFLEET-B Allocates HK$546,400 to Buy Back 20,000 Shares on September 3
Stock News  ·  09-03
GENFLEET-B Allocates HK$546,400 to Buy Back 20,000 Shares on September 3
Genfleet Therapeutics Files HKEX Next-Day Return Disclosing Share Buyback at HKD 27.32
Reuters  ·  09-03
Genfleet Therapeutics Files HKEX Next-Day Return Disclosing Share Buyback at HKD 27.32
GenFleet Reports Stable Share Base in August; Confirms 19.86% Public Float Compliance
Bulletin Express  ·  09-02
GenFleet Reports Stable Share Base in August; Confirms 19.86% Public Float Compliance
GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd
Stock News  ·  09-02
GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd
Genfleet Therapeutics Files HKEX Next-Day Return Disclosing Share Buyback at HKD 27.6 Avg
Reuters  ·  09-02
Genfleet Therapeutics Files HKEX Next-Day Return Disclosing Share Buyback at HKD 27.6 Avg
The Consensus EPS Estimates For GenFleet Therapeutics (Shanghai) Inc. (HKG:2595) Just Fell Dramatically
Simply Wall St.  ·  08-27
The Consensus EPS Estimates For GenFleet Therapeutics (Shanghai) Inc. (HKG:2595) Just Fell Dramatically
GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial
MT Newswires Live  ·  08-26
GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial
HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off
Stock News  ·  08-26
HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off
GenFleet Pushes Lead KRAS G12D Candidate GFH375 into China Phase II First-Line NSCLC Trial, Testing Monotherapy and Combos with Cetuximab or Pemetrexed
Bulletin Express  ·  08-26
GenFleet Pushes Lead KRAS G12D Candidate GFH375 into China Phase II First-Line NSCLC Trial, Testing Monotherapy and Combos with Cetuximab or Pemetrexed
Genfleet Therapeutics (Shanghai) - Gfh375 Enters Phase Ii Study for First-Line Kras G12d-Mutant Nsclc
THOMSON REUTERS  ·  08-26
Genfleet Therapeutics (Shanghai) - Gfh375 Enters Phase Ii Study for First-Line Kras G12d-Mutant Nsclc
GenFleet Therapeutics (Shanghai) Reports Loss of Rmb220.17 Million for Six Months
Reuters  ·  08-21
GenFleet Therapeutics (Shanghai) Reports Loss of Rmb220.17 Million for Six Months
GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion
Bulletin Express  ·  08-21
GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion
Genfleet Therapeutics (Shanghai) - Reports Loss of Rmb220.17 Mln for Six Months Ended June 30, 2026
THOMSON REUTERS  ·  08-21
Genfleet Therapeutics (Shanghai) - Reports Loss of Rmb220.17 Mln for Six Months Ended June 30, 2026
Genfleet Therapeutics (Shanghai) - Reports Revenue of Rmb42.47 Mln for Six Months Ended June 30, 2026
THOMSON REUTERS  ·  08-21
Genfleet Therapeutics (Shanghai) - Reports Revenue of Rmb42.47 Mln for Six Months Ended June 30, 2026
GenFleet Interim Loss Narrows to RMB 220.17 Million in FY26 H1; Revenue Falls to RMB 42.47 Million
Reuters  ·  08-21
GenFleet Interim Loss Narrows to RMB 220.17 Million in FY26 H1; Revenue Falls to RMB 42.47 Million
No data available

Introduction

Company Name.
GENFLEET-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The Company is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The Company mainly primarily operates in the domestic and international markets.
Issue price:
--